Savara Inc

Nasdaq:SVRA

Pharmaceutical Preparations·AUSTIN, TX

Summary Financials

Revenue

$257,000

+0.0% YoY

FY 2021

Adj. EBITDA

-$59.5M

-23144.4% margin

FY 2024

Net Income

-$54.7M

-21283.3% margin

FY 2024

EPS (Diluted)

-$0.33

FY 2024

Stock Price

$5.43

+3.0%

2026-03-09

52W Range

$1.89 – $7.00

P/E Ratio

-16.5x

Market Cap

$1.1B

Cash

$26.6M

FY 2024

Total Debt

$26.3M

FY 2024

Net Cash

$237,000

FY 2024

Enterprise Value

$1.1B

Debt / EBITDA

0.0x

FY 2021

EV / EBITDA

-18.6x

Employees

—

Revenue

$257,000

+0.0% YoY

FY 2021

Adj. EBITDA

-$59.5M

-23144.4% margin

FY 2024

Net Income

-$54.7M

-21283.3% margin

FY 2024

EPS (Diluted)

-$0.33

FY 2024

Stock Price

$5.43

+3.0%

2026-03-09

52W Range

$1.89 – $7.00

P/E Ratio

-16.5x

Market Cap

$1.1B

Cash

$26.6M

FY 2024

Total Debt

$26.3M

FY 2024

Net Cash

$237,000

FY 2024

Enterprise Value

$1.1B

Debt / EBITDA

0.0x

FY 2021

EV / EBITDA

-18.6x

Employees

—